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HasMedicare Part D Reduced Racial/
Ethnic Disparities in Prescription Drug
Use and Spending?
ElhamMahmoudi and Gail A. Jensen
Objective. To evaluate whether Medicare Part D has reduced racial/ethnic disparities
in prescription drug utilization and spending.
Data. Nationally representative data on white, African American, and Hispanic Medi-
care seniors from the 2002–2009Medical Expenditure Panel Survey are analyzed. Five
measures are examined: filling any prescriptions during the year, the number of pre-
scriptions filled, total annual prescription spending, annual out-of-pocket prescription
spending, and average copay level.
Study Design. We apply the Institute of Medicine’s definition of a racial/ethnic
disparity and adopt a difference-in-difference-in-differences (DDD) estimator using a
multivariate regression framework. The treatment group consists of Medicare seniors,
the comparison group, adults withoutMedicare aged 55–63 years.
Principal Findings. Difference-in-difference-in-differences estimates suggest that for
African Americans Part D increased the disparity in annual spending on prescription
drugs by $258 (p = .011), yet had no effect on othermeasures of prescription drug dispar-
ities. For Hispanics, DDD estimates suggest that the program reduced the disparities in
annual number of prescriptions filled, annual total and out-of-pocket spending on pre-
scription drugs by 2.9 (p = .077), $282 (p = .019) and $143 (p < .001), respectively.
Conclusion. Medicare Part D had mixed effects. Although it reduced Hispanic/white
disparities related to prescription drugs among seniors, it increased the African Ameri-
can/white disparity in total annual spending on prescription drugs.
Key Words. Medicare Part D, prescription drugs, utilization and spending, racial/
ethnic disparities
Medicare Part D is the single most important extension to Medicare since the
program’s inception. Part D, which took effect in January 2006, makes pre-
scription drug insurance available to all beneficiaries at a reasonable pre-
mium. Under Part D every beneficiary can purchase a drug insurance plan
from a range of plans offered by private health insurers, with premium subsi-
dies available to persons with low income and few resources.
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In this article we examine whether Medicare Part D has had any effects
on racial/ethnic disparities in prescription drug use and spending. Using
nationally representative data from the 2002–2009 Medical Expenditure
Panel Survey (MEPS), we employ a difference-in-difference-in-differences
(DDD) methodology to isolate the effects of Part D, comparing changes in
racial/ethnic disparities among Medicare seniors that occurred following the
introduction of Part D to changes in racial/ethnic disparities among adults
withoutMedicare, aged 55–63 years, over the same period.
BACKGROUND
Research has documented that prior to 2006 there were substantial racial/eth-
nic disparities in the utilization of prescription drugs among older adults
(Reed, Hargraves, and Cassil 2003; Briesacher, Limcangco, and Gaskin 2004;
Safran et al. 2005; Gaskin et al. 2006; Gellad, Haas, and Safran 2007). Studies
showed that whites used more prescription drugs and had higher total pre-
scription drug expenditures than either African Americans or Hispanics. For
instance, among beneficiaries without drug coverage, African Americans and
Hispanics used 10–40 percent fewer medications, on average, compared to
whites, and they spent up to 60 percent less on their medications (Briesacher
et al. 2004).
Not surprisingly, these differences in utilization and spending were
highly correlated with self-reports of being unable to afford medications, as
well as self-reports of cost-related medication nonadherence (CRN) (Reed
et al. 2003; Wilson, Axelsen, and Tang 2005; Soumerai et al. 2006; Safran
et al. 2010; Gellad, Haas, and Safran 2007). African Americans and Hispanics
were particularly vulnerable to experiencing problems paying for their medi-
cations (Gellad, Haas, and Safran 2007). In 2003, 25 percent of African Ameri-
can and Hispanic seniors, compared to 11 percent of white seniors, reported
spending less on food and other basic needs to pay for prescription drugs, and
40 percent of African Americans and Hispanics reported cost as their reason
for nonadherence to prescribed medications, compared to 28 percent of
whites (Gellad, Haas, and Safran 2007). CRN is known to increase the risk of
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adverse health events, such as a heart attack or stroke, as well as the complica-
tions arising from chronic health conditions, such as diabetes (Heisler et al.
2004; Sokol et al. 2005; Gibson et al. 2010; Jensen and Li 2012).
Previous studies document that Medicare Part D decreased beneficia-
ries’ out-of-pocket costs by approximately 13–18 percent (Lichtenberg and
Sun 2007;Madden et al. 2008; Levy andWeir 2009; Safran et al. 2010; Engel-
hardt and Gruber 2011; Liu et al. 2011). Yet it is not clear whether Part D has
affected racial/ethnic disparities in prescription drug use and spending. This
study examines this issue.
METHODS
Using data from the MEPS, we estimate the effects of Medicare Part D on
disparities in prescription drug utilization and spending using a pre period and
post period with comparison group design, applying the Institute of
Medicine’s definition of a disparity. The pre period for our analysis covers
2002–2005 and the post period covers 2006–2009. Medicare beneficiaries
aged 65 years and older (at the beginning of each year) comprise the “treat-
ment” group, and adults aged 55–63 years (at the beginning of the year) who
do not have Medicare comprise the “comparison” group. In our analysis, we
do not follow the same individuals across the pre period and post period. That
is not possible to do with MEPS. Rather, we compare disparities in prescrip-
tion drug utilization and spending amongMedicare seniors during the pre per-
iod to disparities in these measures among Medicare seniors during the post
period, and then examine whether the changes that occurred were any differ-
ent from the changes in disparities that occurred within the comparison group.
Figure 1 provides a schematic of our research design and sample counts.
Data
We use the Household Component (HC) files of the 2002–2009 MEPS.
MEPS is an ongoing, nationally representative survey of the U.S. civilian,
noninstitutionalized population, conducted annually by the Agency for
Healthcare Research and Quality (AHRQ) (Cohen et al. 1997). We limit our
attention to individuals who self-report being (non-Hispanic) African Ameri-
can, Hispanic, or (non-Hispanic) white, based onMEPS’s questions regarding
race and ethnicity. Other minority groups are not examined due to their small
sample counts inMEPS.
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Our final analytic sample includes a total of 45,463 MEPS respondents,
26,109 of whom are in the treatment group and 19,354 of whom are in the
comparison group. Within the treatment group there were 13,585 individuals
(whites = 10,038; African Americans = 1,794; Hispanics = 1,753) who were
surveyed between 2002 and 2005 and 12,524 individuals (whites = 8,662;
African Americans = 2,183; and Hispanics = 1,679) who were surveyed
between 2006 and 2009. In the comparison group there were 9,337 individu-
als (whites = 6,511; African Americans = 1,315; Hispanics = 1,511) who were
surveyed between 2002 and 2005 and 10,017 individuals (whites = 6,397;
African Americans = 1,775; Hispanics = 1,845) who were surveyed between
2006 and 2009.
Variable-specific nonresponse rates generally ranged from 0 to 5 per-
cent. Two summary indices of overall physical and mental health, however,
showed nonresponse rates in the 7–9 percent range, specifically, the norm-
based physical component summary scale (NBPCS) and the norm-based
mental component summary scale (NBMCS), both calculated from Version 2
of the Short Form 12 Health Survey (SF12-V2) (Ware et al. 2002). We used a
Figure 1: Counts of Individuals in the Treatment and Comparison Groups
before and after Medicare Part D (Overall Total Sample of 45,463 Individu-
als).
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multiple imputation technique (Little and Rubin 2002) to estimate the missing
values for these variables and created five complete sets of data, reestimating
the regression models for each set, re-calculating disparities on each of these
complete sets of data, and then taking the average according to rules in Little
and Rubin (2002) to incorporate the uncertainty of the missing data into the
standard errors.
Throughout, we adjust for the clustered and stratified survey design of
MEPS and weight all estimates using the AHRQ-supplied weights. We used
Stata 12 for all analyses.
Dependent and Independent Variables
We examine racial/ethnic disparities in five measures: (1) whether any pre-
scriptions are filled during the year; (2) the number of prescriptions (including
refills) filled during the year; (3) total positive annual spending on prescription
drugs; (4) out-of-pocket positive annual spending on prescription drugs; and
(5) average copay for prescription drugs, defined as the ratio of out-of-pocket
spending to total spending. In the utilization and expenditures sections of
MEPS, questions were asked regarding each prescription filled during the pre-
vious round, if any were, and the total and out-of-pocket cost of each prescrip-
tion. With each participant’s consent, MEPS staff verified the detailed
prescription information reported using actual pharmacy records. If consent
was not granted, the data are the participant’s own self-reported information.
Any prescriptions filled and the annual number of prescriptions filled are from
the utilization section of MEPS, and total and out-of-pocket annual spending
on prescription drugs are from the expenditures section of MEPS. Before
beginning the analysis, total and out-of-pocket spending were converted to
inflation-adjusted 2007 dollars using the all-items Consumer Price Index.
Andersen’s conceptual framework guides our choice of explanatory
variables for the models to be estimated (Andersen 1968, 1995). Each model
includes need-related variables, such as age, gender, and measures of health
and functioning. We also include predisposing and enabling factors such as
marital status, education, income, health insurance, location, and language. To
control for health and functioning, we include a range of variables. Two (0,1)
indicators for whether self-rated health and self-rated mental health, respec-
tively, are fair or poor, as opposed to good or better, are included in the mod-
els, as well as (0,1) indicators for whether the individual reports any heart
problems, diabetes, asthma, arthritis, or hypertension. For physical function-
ing, we include the number of functional limitations reported. We also include
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two summary indices of overall physical and mental health, specifically, the
NBPCS and the NBMCS. Marital status is measured with a (0,1) indicator for
whether the individual is currently married. Education is measured by a series
of mutually exclusive (0,1) indicators for whether education is less than high
school, college degree, graduate school degree, or another degree, with high
school serving as the reference category. Household income is measured using
four mutually exclusive categories: poor or near poor (household income is
less than 125 percent of the federal poverty level [FPL]), low income (house-
hold income is 125–199 percent of FPL), middle income (household income is
200–399 percent of FPL), and high income (household income is at least 400
percent of FPL), with low income serving as the reference category. For health
insurance we include a (0,1) indicator for whether the individual reports (at
any time during the past year) having Medicaid, as well as (0,1) indicators
describing the nature of their private insurance holdings, specifically, whether
the individual holds HMO coverage, private non-HMO insurance, or has no
private insurance, with the last of these serving as the reference category. We
also control for whether the individual resides in an urban area, and his or her
US Census region, with the Northeast as the reference category. Finally, all
models adjust for English language fluency, with a (0,1) indicator for whether
the individual conducted his or her MEPS interview in English. Table 1
provides descriptive statistics on the variables, reported separately for the
treatment and comparison group.
Institute of Medicine (IOM) Definition and Measurement of a Disparity
We adopt the IOM definition of a racial or ethnic disparity (IOM 2002).1 In its
2002 report, Unequal Treatment: Confronting Racial and Ethnic Disparities in
Health Care, the IOM defines a disparity as “a difference in access or treatment
provided to members of different racial or ethnic groups that is not justified by
the underlying health conditions or treatment preferences of patients.”McGu-
ire et al. (2006) and Cook et al. (2010) describe the methods for implementing
this definition, and we apply their methods here.
Briefly, we use a four-step procedure to calculate disparities. First, for
each outcome measure, we fit a multivariate regression using the explanatory
variables described above that allows for the effects of key explanatory vari-
ables to vary by race and ethnicity. Second, we transform the distribution of
the health status explanatory variables for each minority group to be the same
as their distribution among whites, while leaving the non-need-related
variables unchanged. These transformations are made using the “rank-
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Table 1:Characteristics of the Comparison Group (Individuals without Medi-
care, Aged 55–63 years) and the Treatment Group (Medicare Beneficiaries,
Aged 65 years andOlder) before Part D
Description
Comparison†
(N = 9,337)
Treatment‡
(N = 13,585)
Mean SE Mean SE
Dependent variables
Any prescriptions
filled*
1 if any prescription gets
filled during the year
0.81 0.01 0.93 0.00
Number of pres.
drugs*
Annual number of
prescriptions filled
22.14 0.46 30.18 0.49
Cost of pres. drugs* Total cost of prescription
drugs during the year
1,602.24 37.46 2,056.75 54.12
Out-of-pocket
cost of drugs*
Annual out-of-pocket
cost of prescription
drugs
590.27 15.87 1,058.12 21.65
Copay* Annual out-of-pocket
cost/annual total cost
0.46 0.01 0.58 0.01
Independent variables
Need-related
Age* Age at the beginning of
the year
58.66 0.05 74.40 0.11
Female* 1 if individual is female 0.55 0.01 0.59 0.01
Poor/Fair health* 1 if individual rates her
health as poor/fair
0.18 0.01 0.25 0.01
Poor/Fair
mental health
1 if individual rates his
mental health as poor/
fair
0.07 0.00 0.09 0.00
PCS* Physical component
summary SF12
46.74 0.19 40.60 0.16
MCS Mental component
summary SF12
51.70 0.16 51.62 0.15
Function_index*,§ Index of physical
limitation
3.68 0.14 8.93 0.16
Diabetes* 1 if individual diagnosed
with diabetes
0.14 0.01 0.19 0.01
Heart* 1 if individual has any
heart problem
0.17 0.01 0.34 0.01
Asthma 1 if individual diagnosed
with asthma
0.11 0.01 0.09 0.00
Arthritis* 1 if individual diagnosed
with arthritis
0.41 0.01 0.55 0.01
High blood
pressure*
1 if individual diagnosed
with high blood
pressure
0.51 0.01 0.65 0.01
Continued
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Table 1. Continued
Description
Comparison†
(N = 9,337)
Treatment‡
(N = 13,585)
Mean SE Mean SE
Marital status
Married* 1 if individual is married 0.72 0.01 0.54 0.01
Education
Less than high
school*
1 if individual has no
high school diploma
0.12 0.01 0.27 0.01
High school (omitted) 1 if individual has high
school diploma
0.51 0.01 0.50 0.01
College and
graduate school*
1 if individual has a
college or graduate
degree
0.30 0.01 0.18 0.01
Other degree* 1 if individual has other
degrees
0.08 0.01 0.05 0.00
Household income level
Poor or near poor* 1 if household income <
125% FPL
0.10 0.01 0.17 0.01
Low income (omitted)* 1 if household income is
125–199% FPL
0.08 0.00 0.20 0.01
Middle income* 1 if household income is
200–399% FPL
0.25 0.01 0.30 0.01
High income* 1 if household income
≥400% FPL
0.57 0.01 0.32 0.01
Health insurance
Medicaid* 1 if individual has
Medicaid
0.05 0.00 0.08 0.00
Private HMO insurance* 1 if individual holds
private HMO
insurance
0.31 0.01 0.09 0.01
Private
non-HMO insurance
1 if individual holds
private non-HMO
insurance
0.50 0.01 0.44 0.01
No private*
insurance (omitted)*
1 if individual holds no
private insurance
0.19 0.01 0.46 0.01
Location
Northeast 1 if individual lives in
Northeast
0.20 0.01 0.21 0.01
Midwest 1 if individual lives in
Midwest
0.24 0.01 0.23 0.01
South 1 if individual lives in
South
0.37 0.01 0.37 0.01
West 1 if individual lives in
West
0.19 0.01 0.19 0.01
Continued
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and-replace” method described by Cook et al. (2010, p. 831). Specifically, we
apply Cook et al.’s rank-and-replace techniques to the health status summary
index score obtained from the model we estimate in step one. Third, we then
use the fitted regression from step one to calculate predicted values of the out-
come measure for each minority group member using their transformed
health status summary index score along with their actual values for other
variables in the model. Finally, we average these predictions by population
group and calculate a disparity in the outcome measure as the difference
between the average hypothetical value for that outcome in the minority
group and the average value for that outcome among whites. In the treatment
group, disparities are measured before Part D and then after Part D, and the
same is done in the comparison group. To measure the standard errors for the
IOM predictions, we replicated our entire sample 100 times (with replace-
ment) using Stata’s bootstrapping procedure for the case of complex survey
design (Kolenikov 2010), reestimated the IOM disparities with each boot-
strapped sample, and then calculated the standard deviation of those 100 esti-
mates as the measure of their standard error.
Table 1. Continued
Description
Comparison†
(N = 9,337)
Treatment‡
(N = 13,585)
Mean SE Mean SE
Metropolitan area 1 if individual lives in a
statistical metropolitan
area
0.80 0.01 0.78 0.01
Language
English language 1 if language of the
interview is English
0.97 0.00 0.96 0.00
Note. The variables listed are the explanatory variables in the estimated regression models. Tables
A1–A2 report detailed descriptive statistics stratified by race and ethnicity for the comparison and
treatment groups for the periods before and afterMedicare Part D.
*The mean of this variable differs significantly between the comparison and treatment group at
the alpha = .01 level.
†Comparison group consists of adults without Medicare, aged 55–63 years, who self-report being
white, African American, or Hispanic.
‡Treatment group consists of Medicare beneficiaries, aged 65 years and older, who self-report
being white, African American, or Hispanic.
§Function-Index is an index of limitations on activities of daily living (ADLs) and instrumental
activities of daily living (IADLs).
Source: Data are from the household component files of the 2002–2005Medical Expenditure Panel
Survey.
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Difference-in-Difference-in-Differences and Regression Framework for Evaluation
We adopt a DDD methodology to estimate Part D’s effects on racial/ethnic
disparities in prescription utilization, prescription drug spending, and benefi-
ciary copay levels. DDD methods are valid if, in the absence of Part D, both
the treatment and comparison groups would have experienced similar trends
in racial/ethnic disparities over the period. Before estimating the models we
consider this issue and formally test for trend similarities in the outcome vari-
ables during the years leading up to Part D (see Table 2).
The regression equation below illustrates the basic structure of the mod-
els we estimate before calculating IOM disparities. In this equation, Medicare
seniors comprise the “treatment group,” and adults without Medicare, aged
55–63 years, comprise the “comparison group”:
Yj ¼ b^0 þ Trtj b^1 þ PartDj b^2 þ ðTrtj  Part Dj Þb^3 þ Aj b^0A þ ðAj  Trtj Þb^1Aþ
ðPart Dj  AjÞb^2A þ ðAj  Trtj  Part Dj Þb^3A þ Hj b^0H þ ðHj  TrtjÞb^1Hþ
ðPart Dj HjÞb^2H þ ðHj  Trtj  Part DjÞb^3H þ
XK
i¼1
b^3þiXij þ ej
Here, j indexes an individual and Y is one of the outcomemeasures, such
as total annual spending on drugs. “Part D” is a (0,1) indicator for whether the
individual was surveyed after January 2006 or before then (1 if after, 0 if
before), and “Trt” is a (0,1) indicator for membership in the treatment group (1
if yes, 0 if no). “A” and “H” are (0,1) indicators for whether the individual is
African American or Hispanic, respectively (1 if yes, 0 if no). Finally, the Xi’s
are other relevant explanatory variables, such as demographic and socioeco-
nomic characteristics, and for some of the Xi’s, their interactions with the race/
ethnicity indicators.2
For any prescriptions filled we fit a logistic regression (reported in the
on-line supplemental material for this paper, Table B1). For the positive
number of prescriptions filled and for each positive expenditure measure
we fit a generalized linear model (GLM) (McCullagh and Nelder 1989). On
the basis of a modified Park test (Park 1966) and other recommended diag-
nostics (Manning and Mullahy 2001; Deb, Manning, and Norton 2010), we
chose a GLM with a log link and gamma distribution for the two expendi-
ture measures and chose a GLM with a log link and negative binomial dis-
tribution for the total number of prescriptions filled (Tables B2–B4 in the
on-line supplemental material). Finally, for copay level we fit an ordinary
least squares model.
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In our regressionmodels we treat theMEPS 2006 data as part of the post
Part D period, because Part D took effect from January 1, 2006. However, a
more appropriate approach might be to simply exclude the 2006 data from
the dataset, thereby defining the post period to be 2007–2009. Because many
seniors were still signing up for Part D in the first quarter of 2006, one could
argue they were “not exposed” to their Part D coverage for the full year.
Would our results change if we instead drop the 2006 data? We address this
issue at the end of our results section.
RESULTS
Table 1 provides definitions and descriptive statistics for the variables. The
average age of Medicare seniors (the treatment group) is 74.4 years, and the
average age of adults without Medicare aged 55–63 years (the comparison
group) is 58.7 years. Compared to adults in the comparison group, Medicare
seniors are less healthy and have more functional limitations (e.g., their average
physical component summary score is 40.6 versus 46.7 in the comparison
group (p < .001), and their average functional limitations score is 8.9 versus 3.7
in the comparison group (p < .001)). Medicare seniors also have less formal
education (e.g., 27 percent vs. 12 percent report less than a high school educa-
tion) and have lower annual household income (37 percent vs. 18 percent have
household income that is less than 199 percent of FPL). Tables A1 and A2 in
the on-line supplemental material to this paper provide descriptive statistics
stratified by race/ethnicity for the treatment and comparison groups, respec-
tively.
Table 2 reports the unadjusted trends in the gap between African Ameri-
cans and whites, and between Hispanics and whites in the years leading up to
Part D. Our purpose in examining these trends is to assess whether racial/ethnic
disparities in the treatment and comparison groups appear to have been on sim-
ilar trajectories prior to the intervention of Part D. If not, then DDD methods
are not valid (Bertrand, Duflo, and Mullainathan 2004). The first column in
Table 2 lists each of the outcome variables. The second column reports the
observed differences between African Americans and whites during 2002–
2003, and the third column reports such differences during 2004–2005. The
fourth column reports the changes in the gap over time, and the fifth column
reports the net DDD results between the two time periods and between the
comparison and treatment groups. The right side of Table 2 (columns 7 through
11) reports analogous statistics comparing whites andHispanics.
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The statistics in Table 2 reveal that prior to Part D, the differences in
unadjusted disparity trends were not statistically significant. While prior to
2006 trends in disparities between African Americans/whites in any prescrip-
tions filled, in total number of prescriptions, and in out-of-pocket cost, and
between Hispanics/whites in out-of-pocket cost were diverging between the
comparison and treatment groups, the net differences were not statistically sig-
nificant. The lack of significant differences in these trends between the groups
suggests we can proceed with a DDD approach for evaluating changes in dis-
parities. We return to this point later in the discussion. We now proceed to the
main analysis.
Table 3 reports for the treatment and comparison groups the IOM-
adjusted estimates of the average values for the five outcome measures and
the IOM disparity between whites and African Americans in those outcome
measures, prior to and after Part D. Table 4 is a similar table that compares
whites and Hispanics. The estimates in these two tables were derived from
simulations using the multivariate regressions reported in Tables B1–B5
(reported on-line), after assigning African Americans and Hispanics the
same distribution of need-related variables that whites display.
Tables 3 and 4 reveal that, both before Part D and after it, there were sig-
nificant racial/ethnic disparities in prescription drug utilization and spending
among older adults. In both the treatment and comparison groups, older Afri-
can Americans and Hispanics were significantly less likely than older whites
to fill any prescriptions at all, and to fill fewer when they did fill any. Annual
total and out-of-pocket expenditures on prescription drugs were also signifi-
cantly lower among older African Americans andHispanics than among older
whites. In contrast to the comparison group, prior to and after Part D, older
African Americans and Hispanics had lower average copays for their prescrip-
tion drugs. Following Part D, regardless of race or ethnicity, the average copay
in the treatment group fell by about a third, whereas in the comparison group
it fell by only about 7–9 percent. To assess whether racial/ethnic disparities
actually changed as a result of Part D, we now turn to Table 5, which summa-
rizes our overall key findings.
Table 5 reports estimates of the effects of Part D on the IOM disparities
between minorities and whites, based on the estimated disparities reported in
the last two columns of Tables 3 and 4. The left side summarizes our findings
regarding disparities between African Americans and whites, while the right
side summarizes our findings regarding disparities between Hispanics and
whites. As shown, among seniors the disparity in any prescriptions filled
between African American and white seniors fell by 1 percent (p = .213) fol-
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lowing implementation of Part D. However, in the comparison group the dis-
parity in any prescriptions filled between African Americans and whites also
fell by 1 percent (p = .817). Thus, in the DDD estimate of the “net effect” of
Medicare Part D, which is the difference between these amounts, there was no
reduction (p = .699) in the disparity. DDD estimates show that Part D also
had no significant effects on the African American/white disparity in annual
number of prescriptions filled, in annual out-of-pocket spending on prescrip-
tion drugs, or in average copay level.
Part D had a significant effect on the African American/white disparity
in annual total spending on prescription drugs. The DDD net effect of Part D
was a $258 (p = .011) increase in the disparity in annual total spending. The
Table 3: Institute of Medicine Estimates of Outcomes Related to Prescrip-
tion Drugs for the Comparison and Treatment Groups during 2002–2005 and
2006–2009 between whites and African Americans
whites African Americans Disparities
Outcome Measures 02–05 06–09 02–05 06–09 02–05 06–09
Any prescriptions filled
Treatment (65+) 93% 93% 85%*** 86%*** 8% 7%
Comparison (55–63) 83% 82% 69%*** 69%*** 14% 13%
Total number Rx filled
Treatment (65+) 30.94 33.36 28.85* 29.95*** 2.09 3.41
Comparison (55–63) 21.60 22.01 18.64*** 19.40*** 2.96 2.61
Rx total spending
Treatment (65+) $2,161.73 $2,399.75 $1,850.40*** $1,876.40*** $311.33 $523.35++
Comparison (55–63) $1,594.13 $1,754.46 $1,165.51*** $1,371.43*** $428.62 $383.03
Rx out-of-pocket
Treatment (65+) $1,113.07 $735.14 $782.38*** $455.30*** $330.69 $279.84++
Comparison (55–63) $582.13 $509.34 $412.29*** $389.32*** $169.84 $120.02+++
Average copay
Treatment (65+) 59% 38% 53%*** 32%*** 6% 6%
Comparison (55–63) 45% 41% 49%*** 45%*** 4% 4%
Note: Estimates of number of prescriptions filled, total prescription cost, and out-of-pocket cost are
based on samples with positive amounts of utilization and expenditure. Estimates for the compari-
son and treatment groups are based on the adjusted regression models reported in Tables B1–B5.
Comparison group consists of adults without Medicare, aged 55–63, who self-report being white,
African American, or Hispanic. Treatment group consists of Medicare beneficiaries aged 65 and
older, who self-report being white, African American, or Hispanic.
*, *** Significantly different from the estimate for whites at the alpha = .10, .05, and .01 level,
respectively.
++, +++ Significantly different from the 2002–2005 estimate at the alpha = .10, .05 and .01 level,
respectively.
Source: Data are from the household component files of the 2002–2009Medical Expenditure Panel
Survey.
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increase occurred because the disparity in total spending rose $212 among
Medicare seniors (p = .015) following Part D, but it also fell $46 among near-
elders (p = .502). The DDD net effect of Part D is the difference between these
amounts, which is $212-(-$46) or $258. Following Part D total spending on
drugs rose among both white and African American seniors, but it rose more
among whites than among African Americans, hence the increase by $212 in
the disparity for this group.
Part D also had a few significant effects on disparities between Hispanic
and white seniors. Although Part D had no DDD net effect on the disparity in
any prescriptions filled or the disparity in average copay, the program did
reduce Hispanic/white disparities in each of the other three utilization and
Table 4: Institute of Medicine Estimates of Outcomes Related to Prescrip-
tion Drugs for the Comparison and Treatment Groups during 2002–2005 and
2006–2009 between whites and Hispanics
whites Hispanics Disparities
Outcome measures 02–05 06–09 02–05 06–09 02–05 06–09
Any prescriptions filled
Treatment (65+) 93% 93% 88%*** 88%*** 5% 5%
Comparison (55–63) 83% 82% 70%*** 69%*** 13% 13%
Total number Rx filled
Treatment (65+) 30.94 33.36 26.39*** 30.58*** 4.55 2.78
Comparison (55–63) 21.60 22.01 17.44*** 16.74*** 4.16 5.27
Rx total spending
Treatment (65+) $2,161.73 $2,399.75 $1,697.39*** $1,912.37*** $464.34 $487.38
Comparison (55–63) $1,594.13 $1,754.46 $1,185.12*** $1,040.76*** $409.01 $713.70+++
Rx out-of-pocket
Treatment (65+) $1,113.07 $735.14 $775.34*** $453.39*** $337.73 $281.75
Comparison (55–63) $582.13 $509.34 $496.43*** $336.66*** $85.70 $172.68+++
Average copay
Treatment (65+) 59% 38% 52%*** 30%*** 7% 8%
Comparison (55–63) 45% 41% 55%*** 51%*** 10% 10%
Note. Estimates of number of prescriptions filled, total prescription cost, and out-of-pocket cost are
based on samples with positive amounts of utilization and expenditure. Estimates for the compari-
son and treatment groups are based on the adjusted regression models reported in Tables B1–B5.
Comparison group consists of adults without Medicare, aged 55–63, who self-report being white,
African American, or Hispanic. Treatment group consists of Medicare beneficiaries aged 65 and
older, who self-report being white, African American, or Hispanic.
*** Significantly different from the estimate for whites at the alpha = .10, .05, and .01 level, respec-
tively.
+++ Significantly different from the 2002–2005 estimate at the alpha = .10, .05 and .01 level,
respectively.
Source: Data are from the household component files of the 2002–2009Medical Expenditure Panel
Survey.
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spending measures. The DDD net effect of Part D on the Hispanic/white
disparity in total number of prescriptions filled annually was a drop of 2.88
prescriptions (p = .077). The DDD net effect of the program on the Hispanic
/white disparity in total annual spending on prescription drugs was a $282
(p = .019) drop, and the DDD net effect on the Hispanic/white disparity in
annual out-of-pocket spending on drugs was a $143 (p < 0.001) drop.
When we reestimated all of these models without inclusion of the 2006
data, our findings barely changed. Specifically, our estimates of any prescrip-
tions filled and the number of prescriptions filled were effectively the same
(rounding to two decimals) for each subpopulation as they were before. With-
out 2006 data, our estimated disparities for total and out-of-pocket prescrip-
tion drug spending in the treatment group were slightly different (by $61 and
$4, respectively, for whites vs. Hispanics, and by $1 and $3, respectively, for
whites vs. African Americans).
DISCUSSION
Three main findings emerge from this analysis. First, based on a DDD econo-
metric approach, Medicare Part D significantly increased the disparity
between African American and white seniors in total annual spending on pre-
scription drugs by $258.
Second, Part D significantly reduced Hispanic/white disparities in the
annual number of prescriptions filled, in total annual spending on prescription
drugs, and in annual out-of-pocket spending on prescription drugs. Due to
Part D, these disparities fell by 2.88, $282, and $143, respectively, based on
DDDmeasures of change.
Third, Part D had no effects on African American/white disparities in
whether any prescriptions filled, in the number of prescriptions, on annual
out-of-pocket spending on drugs, or on average copay. Nor did Medicare Part
D have any effects on the Hispanic/white disparity in filling any prescriptions
during a year or on average copay.
African Americans’ disparity increase in annual total spending on pre-
scription drugs is attributable to two things: a larger increase in annual total
spending among white seniors than among African American seniors, and to a
reduction in the total spending disparity among near-elders. While white
seniors experienced large increases in both the number of prescriptions filled
(by 8 percent) and total spending on drugs (by 11 percent) after Part D, both of
these measures increased minimally (by 1 percent) among African American
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seniors. On the other hand, while there was no significant increase in number
of prescriptions filled among African American near-elders, their total spend-
ing on prescription drugs rose substantially (by 18 percent).
Hispanic seniors, falling disparities are attributable to increases in their
prescription drug utilization and spending vis-a-vis whites. We note here that
those increases in utilization and spending among Hispanics were large
enough to essentially lift them onto the same footing as African Americans.
That is, adjusted average utilization and spending on prescription drugs are
now quite similar for African American and Hispanic seniors, whereas prior
to Part D they were significantly lower for Hispanics.
One explanation for why Hispanics saw large changes in utilization and
spending may be their higher rate of enrollment in Medicare Advantage (MA)
plans that have drug coverage, as opposed to stand-alone drug plans (Neu-
man, Strollo, and Cuterman 2007; Levy and Weir 2009). It is also worth not-
ing that, as shown in Table 5, among adults aged 55–63 racial/ethnic
disparities in several of these outcome variables actually worsened between
the early and later part of the decade. We think these trends are explained by
the great economic recession that began in December 2007, and the fact that
disproportionately more Hispanics lost employer-sponsored health insurance
over this period, which is the main source of drug insurance among non
elderly adults (Mahmoudi and Jensen 2012).
Although Part D reduced Hispanic/white disparities in prescription
drug utilization and spending, it is still the case that significant disparities
remain both for Hispanic and African American seniors. Why? The
persistence in these disparities may be due to a number of factors. First,
there are still differences in sources of prescription drug coverage across
subpopulations, and different sources provide different depths of insur-
ance protection. Generally speaking, employer plans tend to offer the
most generous drug benefits, followed by MA plans, and stand-alone
drug plans (Neuman et al. 2007). After Part D, most seniors who had
employer-sponsored plans kept their employer-sponsored drug insurance
(Levy and Weir 2009). In our data relatively fewer African American
and Hispanic seniors reported holding employer-sponsored coverage.
Many said they had an MA plan or Medicaid. Thus, differences in the
nature of drug insurance across populations may partially explain this
persistence of disparities. However, other reasons have to do with the
determinants of drug use and spending, more generally. African Ameri-
can and Hispanics more often lack any usual source of care, more fre-
quently encounter transportation difficulties, and tend to have lower
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income, less education, and sometimes English language barriers, all of
which depress their use of health care, including prescription drugs (Coo-
per, Hill, and Powe 2002; Chin et al. 2007; Mahmoudi and Jensen 2012,
2013).
One question that inevitably arises when considering racial/ethnic dis-
parities is whether the higher utilization and spending on prescription drugs
among whites represents “overuse” or whether the lower utilization and
spending among African Americans and Hispanics represents “underuse.”
Just because health care disparities exist does not imply underuse is occurring
in minority populations. It could be that some overuse is occurring among
whites. This study has not addressed this issue. Until the optimal utilization of
prescription drugs is known, it will remain unanswered and an important issue
for research.
This analysis is not without limitations. First, the most suitable com-
parison group would have been a group of Medicare beneficiaries aged
65 and older who were not eligible for Part D. Unfortunately, no such
group exists, so like most prior studies (Basu, Yin, and Alexander 2010;
Liu et al. 2011), we chose adults aged 55–63 without Medicare as our
comparison group. Second, our DDD research design is unable to fully
disentangle the effects of Part D from the effects of changes in Medicare’s
MA program that were also occurring post-2003 (McGuire, Newhouse,
and Sinaiko 2011). Thus, the changes in disparities uncovered here are
likely partly attributable to growth in MA enrollments among minority
seniors, because many MA plans were adding drug coverage over this
period. Recall, we uncovered some subtle differences in Table 2 between
the treatment and comparison groups in the pre-2006 trends in dispari-
ties. Even though we determined those differences were statistically insig-
nificant, they raise a question of whether our comparison and treatment
groups would have indeed experienced similar trends in disparities absent
Part D. One reason to suspect they might not have has to do with some
other changes to Medicare that occurred under the 2003 Medicare Mod-
ernization and Improvement Act (MMA). In addition to creating Part D,
the MMA also changed the MA program in important ways. Specifically,
Medicare began subsidizing payments to MA plans in 2004, and with
those additional payments many MA plans expanded their benefits,
including prescription drug benefits. As a result, many more seniors
enrolled in MA plans (McGuire et al. 2011). From 2002 to 2007, the per-
iod we study here, MA enrollments rose 50 percent, or from 5.6 to 8.4
million (Gold et al. 2012). MA enrollment was related to race and ethnic-
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ity, with minorities more likely to enroll (Shimada et al. 2009; Levy and
Weir 2009). For this reason, racial/ethnic differences in utilization and
spending on prescription drugs among Medicare seniors may have
already started on a different trajectory post-2003, vis- a -vis racial/ethnic
differences in the comparison group. In other words, the changes in
Medicare’s MA program that were also occurring may have influenced
the trajectories in prescription drug disparities. What this means is that
we cannot fully disentangle the effects of Part D from the effects of
changes in Medicare’s MA program that were simultaneously occurring.
Third, there may be differences in preferences and attitudes across racial/
ethnic groups that we are unable to measure, and these may have also
contributed to racial/ethnic disparities in access and utilization (Ayanian
et al. 1999). Fourth, because of their small sample sizes in MEPS, we
were unable to distinguish between Cubans, Puerto Ricans, Mexicans,
and other Hispanics within the overall Hispanic population. Finally, in
this analysis, we examined all Medicare seniors. Thus, our results might
differ for specific subgroups of Medicare beneficiaries, such as seniors
with specific chronic conditions.
In summary, Medicare Part D increased the African American/white
disparity in total annual spending on prescription drugs, with no effects on
other African American/white measures of disparities in prescription drugs.
For Hispanic/white disparities, however, Medicare Part D reduced disparities
in the annual number of prescriptions filled, and in total and out-of-pocket
annual spending on prescription drugs, with no effects on filling any prescrip-
tions or on average copay.
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NOTES
1. We also estimated disparities using two other alternative definitions of a racial/eth-
nic disparity: the unadjusted difference across groups in the average value of the out-
come measure, and the “residual direct effect” estimate of a disparity (Cook,
McGuire, and Miranda 2007). Due to space limitations these results are not pre-
sented or discussed in this article. However, these estimates that apply alternative
definitions are available from the authors upon request.
2. We also tested the “variance inflation factors” to verify that eachmodel was multicol-
linearity-free (Kmenta 1971).
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